Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7–10% of the general population.
DelveInsight's "Chronic Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Neuropathic Pain, historical and forecasted epidemiology as well as the Chronic Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some facts of Chronic Neuropathic Pain Market:
- Chronic Neuropathic Pain is more frequent in women (8% vs. 5.7% in men) and in patients >50 years of age (8.9% vs. 5.6% in those <49 years of age), and most commonly affects the lower back and lower limbs, neck and upper limbs.
- According to an article by Melillo (2020), published on the American Journal of Managed Care, in France the prevalence of chronic neuropathic pain is around 6.9%.
- Of the emerging therapies, the most anticipated product to get launched is AP-325. Apart from this, several other molecules are in early clinical stage or completed clinical studies such as CNTX-6016, KCP-506, HPI201, and others.
- As per the article by Yu et al. (2020), titled “Neuromodulation Management of Chronic Neuropathic Pain in the Central Nervous System,” chronic neuropathic pain is a widespread condition that affects 7–8% of the total population.
- The United States has the highest percentage of prevalent diagnosed and treated patients (2018-2030)
- Neuropathic pain underlies an estimated 30–65% of the activity seen at hospital pain clinics.
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for a Sample Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Chronic Neuropathic Pain Market Report Highlights:
- The report covers the descriptive overview of Chronic Neuropathic Pain, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Chronic Neuropathic Pain epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Neuropathic Pain are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Chronic Neuropathic Pain market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Neuropathic Pain market
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for a Sample Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Central Neuropathic Pain results include multiple sclerosis (MS), spinal cord injury (SCI), central post stroke pain, and Parkinson disease.
Neuropathic pain is usually caused by chronic, progressive nerve disease, and it can also occur as the result of injury or infection. Chronic neuropathic pain, can flare up at any time without an obvious pain-inducing event or factor. Acute neuropathic pain which is uncommon, can occur as well.
Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy. Neuropathic pain may result from disorders of the peripheral nervous system or the central nervous system (brain and spinal cord). Thus, neuropathic pain may be divided into peripheral neuropathic pain, central neuropathic pain, or mixed (peripheral and central) neuropathic pain.
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for a Sample Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Key Chronic Neuropathic Pain Companies covered:
- Algiax Pharmaceuticals
- Centrexion Therapeutics
- Kineta
- MedinCell
- And Many Others
Chronic Neuropathic Pain Drugs covered:
- AP-325
- CNTX-6016
- α9α10 nAChR (KCP-506)
- mdv-NVA
- And Many Others
Request for a Sample Page: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Table of Contents:
- Key Insights
- Executive Summary of Hemophilia B
- Competitive Intelligence Analysis for Hemophilia B
- Hemophilia B: Market Overview at a Glance
- Hemophilia B: Disease Background and Overview
- Patient Journey
- Hemophilia B Epidemiology and Patient Population
- Treatment Algorithm, Current Treatment, and Medical Practices
- Unmet Needs
- Key Endpoints of Hemophilia B Treatment
- Marketed Products
- Emerging Therapies
- Hemophilia B: Seven Major Market Analysis
- Attribute analysis
- 7MM: Market Outlook
- Access and Reimbursement Overview of Hemophilia B
- KOL Views
- Market Drivers
- Market Barriers
- Appendix
- DelveInsight Capabilities
- Disclaimer
View Report: https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Request for Detailed TOC: https://www.delveinsight.com/sample-request/chronic-neuropathic-pain-market
Related Reports:
- Intrahepatic Cholangiocarcinoma Market
- Barett Esophagus Market
- Aortic Stenosis Market
- Chemotherapy Induced Diarrhea Market
- Immunologic Deficiency Syndrome Market
- Binge Eating Disorder Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
